Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphomaWILDIERS, Hans; REISER, Marcel.Critical reviews in oncology/hematology. 2011, Vol 77, Num 3, pp 221-240, issn 1040-8428, 20 p.Article

Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic reviewBOHLIUS, Julia; REISER, Marcel; SCHWARZER, Guido et al.British journal of haematology. 2003, Vol 122, Num 3, pp 413-423, issn 0007-1048, 11 p.Article

Long-Term Survival with Favorable Cognitive Outcome after Chemotherapy in Primary Central Nervous System LymphomaJUERGENS, Annika; PELS, Hendrik; SCHACKERT, Gabriele et al.Annals of neurology. 2010, Vol 67, Num 2, pp 182-189, issn 0364-5134, 8 p.Article

Treatment of relapsed CD20⁺ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: Results of a phase 2 trial of the German Hodgkin Lymphoma Study GroupREHWALD, Ute; SCHULZ, Holger; ENGERT, Andreas et al.Blood. 2003, Vol 101, Num 2, pp 420-424, issn 0006-4971, 5 p.Article

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaHOSIER, Eva; DREYLING, Martin; PETER, Norma et al.Blood. 2008, Vol 111, Num 2, pp 558-565, issn 0006-4971, 8 p.Article

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma : results of a prospective randomized trial of the european MCL networkDREYLING, Martin; LENZ, Georg; BOIRON, Jean-Michel et al.Blood. 2005, Vol 105, Num 7, pp 2677-2684, issn 0006-4971, 8 p.Article

Randomized Study to evaluate the use of high-dose therapy as part of primary treatment for aggressive LymphomaKAISER, Ulrich; UEBELACKER, Irmgard; FRANKE, Astrid et al.Journal of clinical oncology. 2002, Vol 20, Num 22, pp 4413-4419, issn 0732-183X, 7 p.Article

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma : A systematic review and meta-analysisSCHULZ, Holger; BOHLIUS, Julia F; ENGERT, Andreas et al.Journal of the National Cancer Institute. 2007, Vol 99, Num 9, pp 706-714, issn 0027-8874, 9 p.Article

Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patientAWERKIEW, Sabine; DÄUMER, Martin; REISER, Marcel et al.Journal of clinical virology. 2007, Vol 38, Num 1, pp 83-86, issn 1386-6532, 4 p.Article

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHLPFREUNDSCHUH, Michael; TRÜMPER, Lorenz; HASENCLEVER, Dirk et al.Blood. 2004, Vol 104, Num 3, pp 634-641, issn 0006-4971, 8 p.Article

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemiaSCHULZ, Holger; KLEIN, Saskia Karina; HALLEK, Michael et al.Blood. 2002, Vol 100, Num 9, pp 3115-3120, issn 0006-4971, 6 p.Article

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas : Results of a prospective randomized trial of the german low-grade lymphoma study groupNICKENIG, Christina; DREYLING, Martin; HOSTER, Eva et al.Cancer. 2006, Vol 107, Num 5, pp 1014-1022, issn 0008-543X, 9 p.Article

Dose-intensified treatment of advanced-stage diffuse large B-cell lymphomasHELD, Gerhard; SCHUBERT, Joerg; REISER, Marcel et al.Seminars in hematology. 2006, Vol 43, Num 4, pp 221-229, issn 0037-1963, 9 p.Article

Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index C_iSTAIB, Peter; STALTMEIER, Elke; NEUROHR, Katja et al.British journal of haematology. 2005, Vol 128, Num 6, pp 783-791, issn 0007-1048, 9 p.Article

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxombicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone : Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. CommentaryWILSON, Wyndham H; HIDDEMANN, Wolfgang; HEGEWISCH-BECKER, Susanna et al.Blood. 2005, Vol 106, Num 12, issn 0006-4971, 10 p., 3678-3679,3725-3732 [10 p.]Article

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCLMÜLLER, Carsten; MURAWSKI, Niels; METZNER, Bernd et al.Blood. 2012, Vol 119, Num 14, pp 3276-3284, issn 0006-4971, 9 p.Article

Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (MegaCHOEP) and autologous stem cell transplantation : Early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphomaSCHMITZ, Nobert; KLOESS, Marita; GLASS, Bertram et al.Cancer. 2006, Vol 106, Num 1, pp 136-145, issn 0008-543X, 10 p.Article

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHLPFREUNDSCHUH, Michael; TRÜMPER, Lorenz; SCHMITZ, Norbert et al.Blood. 2004, Vol 104, Num 3, pp 626-633, issn 0006-4971, 8 p.Article

Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I studySCHWEIGHOFER, Carmen D; TUCHSCHERER, Armin; HALLEK, Michael et al.Cancer immunology and immunotherapy. 2012, Vol 61, Num 12, pp 2367-2373, issn 0340-7004, 7 p.Article

Improvement of Overall Survival in Advanced Stage Mantle Cell LymphomaHERRMANN, Annina; HOSTER, Eva; WÖRMANN, Bernhard et al.Journal of clinical oncology. 2009, Vol 27, Num 4, pp 511-518, issn 0732-183X, 8 p.Article

Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma : long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)SCHULZ, Holger; REHWALD, Ute; REISER, Marcel et al.Blood. 2008, Vol 111, Num 1, pp 109-111, issn 0006-4971, 3 p.Article

A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivoPOGGE VON STRANDMANN, Elke; HANSEN, Hinrich P; HALLEK, Michael et al.Blood. 2006, Vol 107, Num 5, pp 1955-1962, issn 0006-4971, 8 p.Article

Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia : Results of a phase II trialELTER, Thomas; BORCHMANN, Peter; RECH, Jurgen et al.Journal of clinical oncology. 2005, Vol 23, Num 28, pp 7024-7031, issn 0732-183X, 8 p.Article